Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
- PMID: 36740078
- DOI: 10.1016/j.ijpharm.2023.122660
Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
Abstract
Biologicals including monoclonal antibodies are the current flagships in pharmaceutical industry. However, they are exposed to a multitude of destabilization conditions like for instance hydrophobic interfaces, leading to reduced biological activity. Polysorbates are commonly applied to effectively stabilize these active pharmaceutical ingredients against colloidal stress. Nevertheless, chemical instability of polysorbate via hydrolysis or oxidation results in degradation products that might form particles via phase separation. Polysorbates are mixtures of hundreds of individual components, and recently purer quality grades with reduced variations in the fatty acid composition are available. As the protective function of polysorbate itself is not completely understood, even less is known about its individual components, raising the question of the existence of a superior polysorbate species in respect to protein stabilization or degradation susceptibility. Here, we evaluated the protective function of four main fractions of polysorbate 20 (PS20) in agitation studies with monoclonal antibodies, followed by particle analysis as well as protein and polysorbate content determination. The commercially-available inherent mixtures PS20 high purity and PS20 all-laurate, as well as the fraction isosorbide-POE-monolaurate showed superior protection against mechanical-induced stress (visual inspection and turbidity) at the air-water interface in comparison to sole sorbitan-POE-monolaurate, -dilaurate, and -trilaurate. Fractions composed mainly of higher-order esters like sorbitan-POE-dilaurate and sorbitan-POE-trilaurate indicated high turbidities as indication for subvisible and small particles accompanied by a reduced protein monomer content after agitation. For the isosorbide-POE-monolaurates as well as for the inherent polysorbate mixtures no obvious differences in protein content and protein aggregation (SEC) were observed, reflecting the observations from visual appearance. However, absolute polysorbate concentrations vary drastically between different species in the actual formulations. As there are still open questions in respect to protein specificity or regarding mixtures versus individual components of PS20, further studies must be performed, to gain a better understanding of a "generalized" stabilizing effect of polysorbates on monoclonal antibodies. The knowledge of the characteristics of individual polysorbate species can have the potential to pave the way to superior detergents in respect to protein stabilization and/or degradation susceptibility.
Keywords: Biotherapeutic formulations; Fractionation; Particle formation; Polysorbate 20; Protein stability; Surfactants; Tween®20.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.Mol Pharm. 2020 Jul 6;17(7):2345-2353. doi: 10.1021/acs.molpharmaceut.0c00093. Epub 2020 Jun 5. Mol Pharm. 2020. PMID: 32442382
-
A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.Pharm Res. 2021 Mar;38(3):531-548. doi: 10.1007/s11095-021-03021-z. Epub 2021 Mar 12. Pharm Res. 2021. PMID: 33713012
-
Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.Molecules. 2022 Oct 1;27(19):6497. doi: 10.3390/molecules27196497. Molecules. 2022. PMID: 36235038 Free PMC article.
-
Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.J Pharm Sci. 2008 Aug;97(8):2924-35. doi: 10.1002/jps.21190. J Pharm Sci. 2008. PMID: 17973307 Review.
-
Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.Int J Pharm. 2018 Dec 1;552(1-2):422-436. doi: 10.1016/j.ijpharm.2018.10.008. Epub 2018 Oct 6. Int J Pharm. 2018. PMID: 30300706 Review.
Cited by
-
Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations.J Chem Inf Model. 2024 Jan 8;64(1):265-275. doi: 10.1021/acs.jcim.3c01898. Epub 2023 Dec 19. J Chem Inf Model. 2024. PMID: 38113509 Free PMC article.
-
Stability of Protein Pharmaceuticals: Recent Advances.Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27. Pharm Res. 2024. PMID: 38937372 Review.
-
Discrimination of polysorbate 20 by high-performance liquid chromatography-charged aerosol detection and characterization for components by expanding compound database and library.J Pharm Anal. 2024 May;14(5):100929. doi: 10.1016/j.jpha.2023.12.019. Epub 2023 Dec 30. J Pharm Anal. 2024. PMID: 38799234 Free PMC article.
-
Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives.Front Bioeng Biotechnol. 2025 Jan 10;12:1490276. doi: 10.3389/fbioe.2024.1490276. eCollection 2024. Front Bioeng Biotechnol. 2025. PMID: 39867473 Free PMC article. Review.
-
Oxidation of polysorbates - An underestimated degradation pathway?Int J Pharm X. 2023 Jul 27;6:100202. doi: 10.1016/j.ijpx.2023.100202. eCollection 2023 Dec 15. Int J Pharm X. 2023. PMID: 37680877 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials